ReviewDermatologic therapy2021
Pityriasis rosea-like cutaneous eruption as a possible dermatological manifestation after Oxford-AstraZeneca vaccine: Case report and brief literature review.
Review in Dermatologic therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis.European journal of medical research · 2023Pooled it
- New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review.American journal of clinical dermatology · 2022Pooled it
- Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID-19 vaccination: A systematic review and meta-analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Pooled it
- SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review.International journal of dermatology · 2022Pooled it
- Pityriasis following COVID-19 vaccinations: a systematic review.Dermatology reports · 2024Article
- Article
- L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter].Clinical, cosmetic and investigational dermatology · 2024Article
- L-lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Letter].Clinical, cosmetic and investigational dermatology · 2024Article
- Pityriasis Rosea and Pityriasis Rosea-like Eruption Following COVID-19 Vaccinations: Case Series from Oman.Oman medical journal · 2023Article
- What's old is new: Valacyclovir for the treatment of pityriasis rosea, a retrospective case series.JAAD case reports · 2023Article
- A Review of Pityriasis Rosea in Relation to SARS-CoV-2/COVID-19 Infection and Vaccination.Cureus · 2023Review
- Pityriasis rosea and pityriasis rosea-like eruption after anti-SARS-CoV-2 vaccination: a report of five cases and review of the literature.Dermatology reports · 2023Article
- Article
- Pearls and pitfalls: Adverse cutaneous reactions after COVID-19 vaccination.Allergy and asthma proceedings · 2022Review
- Development of severe pemphigus vulgaris following ChAdOx1 nCoV-19 vaccination and review of literature.Journal of cosmetic dermatology · 2022Review
- Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine.Cureus · 2022Article
- Article
- Viruses, Variants, and Vaccines: How COVID-19 Has Changed the Way We Look at Skin.Current dermatology reports · 2022Review
- Inverse pityriasis rosea secondary to COVID-19 vaccination.Proceedings (Baylor University. Medical Center) · 2022Article
- Pityriasis rosea-like cutaneous eruption as a possible dermatological manifestation after Oxford-AstraZeneca vaccine: Case report and brief literature review.Dermatologic therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pityriasis rosea (PR) has been manifested in patients suffering from COVID-19 as well as after vaccine protocols against SARS-CoV-2. It has a possible association with the HHV-6B virus (roseola infantum) and can be controlled by antivirals such as acyclovir as well as by the amino acid l-Lysine that showed a positive result in reducing the number of lesions and healing time. The aim of this study was to report a case of PR after a second dose of Oxford-AstraZeneca, the adopted therapy and a brief literature review. A 53-year-old woman, phototype II, presented an erythematous lesion in the posterior right thigh 15 days after the second dose of Oxford-AstraZeneca vaccine. Eight days after the initial injury, new injuries appeared in the calf, buttocks and thighs. The diagnosis was PR with a 5-week eruption cycle. The treatment consisted of the use of l-Lysine, 3 grams loading dose and 500 mg for 30 days and moisturizing/healing lotion, starting 14 days after the herald patch. After the 5th week of the disease cycle, there were no new eruptions and the repair cycle continued for up to 8 weeks leaving some residual skin spots. It is concluded that the patient may be a carrier a latent virus, HHV-6, and the vaccine administration with immune system stimulation, would have activated the possible virus causing PR. l-Lysine helped to control the manifestation by limiting the number of lesions and their location, which were restricted to the legs, thighs and buttocks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.